STIM official logo STIM
STIM 4-star rating from Upturn Advisory
Neuronetics Inc (STIM) company logo

Neuronetics Inc (STIM)

Neuronetics Inc (STIM) 4-star rating from Upturn Advisory
$1.52
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: STIM (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 4 star rating for performance

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

1 star rating from financial analysts

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5 Target price
52w Low $1.1
Current$1.52
52w High $5.92

Analysis of Past Performance

Type Stock
Historic Profit 164.87%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 104.10M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 4
Beta 0.71
52 Weeks Range 1.10 - 5.92
Updated Date 12/14/2025
52 Weeks Range 1.10 - 5.92
Updated Date 12/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.83

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -34.27%
Operating Margin (TTM) -19.63%

Management Effectiveness

Return on Assets (TTM) -21.21%
Return on Equity (TTM) -218.99%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 166701601
Price to Sales(TTM) 0.8
Enterprise Value 166701601
Price to Sales(TTM) 0.8
Enterprise Value to Revenue 1.28
Enterprise Value to EBITDA -2.02
Shares Outstanding 68485922
Shares Floating 38810287
Shares Outstanding 68485922
Shares Floating 38810287
Percent Insiders 15.59
Percent Institutions 61.49

About Neuronetics Inc

Exchange NASDAQ
Headquaters Malvern, PA, United States
IPO Launch date 2018-06-28
President, CEO & Director Mr. Keith J. Sullivan
Sector Healthcare
Industry Medical Devices
Full time employees 716
Full time employees 716

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.